Literature DB >> 23857409

The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Fabian Mairinger, Claudia Vollbrecht, Thomas Mairinger, Helmut Popper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23857409     DOI： 10.1097/JTO.0b013e31829b1cf9

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Authors:  R F H Walter; F D Mairinger; S Ting; C Vollbrecht; T Mairinger; D Theegarten; D C Christoph; K W Schmid; J Wohlschlaeger
Journal:  Br J Cancer       Date:  2015-02-10       Impact factor: 7.640

2.  microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.

Authors:  Robert Fred Henry Walter; Claudia Vollbrecht; Robert Werner; Jeremias Wohlschlaeger; Daniel Christian Christoph; Kurt Werner Schmid; Fabian Dominik Mairinger
Journal:  Oncotarget       Date:  2016-04-05

3.  Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Authors:  Fabian D Mairinger; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Elena Mairinger; Jens Kollmeier; Thomas Hager; Thomas Mairinger; Daniel C Christoph; Robert F H Walter; Wilfried E E Eberhardt; Till Plönes; Jeremias Wohlschlaeger; Bharat Jasani; Kurt Werner Schmid; Agnes Bankfalvi
Journal:  Oncotarget       Date:  2018-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.